BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
Terminated · Phase 1 · NCT05935098
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor
At a glance
- Research payments reported, 2025
- $178,107
- U.S. investigators named
- 4
- Sites paid
- 3
- Planned or actual enrollment
- 99
About the trial
- Sponsor
- BeiGene
- Tested
- BGB-A3055 (drug), Tislelizumab (drug), Chemotherapy (drug)
- Dates
- Started 2023-08-21; completion 2026-01-27
- Results posted
- Not yet
This study aims to evaluate how safe and well-tolerated the treatment is, how the body processes it, how it works on the tumors, and whether it shows early signs of fighting cancer in people with certain advanced or metastatic solid tumors. Key details of the study include: * The study is expected to last about 36 months. * Participants will receive treatment until they either no longer benefit from the treatment, experience side effects that are too severe, or choose to stop participating.
From ClinicalTrials.gov, last updated 2026-03-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $178,107 in research payments for this study in 2025 (29 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Douglas E. Laux, MD Hematology & Oncology · Iowa City, IA
- Martin E. Gutierrez, MD Medical Oncology · Hackensack, NJ
- Muhammad Furqan, M.D Medical Oncology · Oklahoma City, OK
- Shiraj Sen, M.D. Hematology & Oncology · Irving, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.